Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 14 | 2025 | 615 | 5.870 |
Why?
|
| Hypertension, Pregnancy-Induced | 7 | 2025 | 49 | 5.270 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 5 | 2025 | 44 | 4.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 4 | 2026 | 38 | 2.140 |
Why?
|
| Blood Pressure | 11 | 2025 | 528 | 1.770 |
Why?
|
| Pregnancy | 17 | 2026 | 2375 | 1.590 |
Why?
|
| Cardiovascular Diseases | 8 | 2025 | 866 | 1.590 |
Why?
|
| Antihypertensive Agents | 6 | 2025 | 178 | 1.540 |
Why?
|
| Cardiomyopathies | 3 | 2024 | 137 | 1.500 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2025 | 58 | 1.300 |
Why?
|
| Dietary Approaches To Stop Hypertension | 4 | 2023 | 9 | 1.250 |
Why?
|
| Heart Failure | 7 | 2026 | 961 | 1.190 |
Why?
|
| Troponin I | 3 | 2025 | 36 | 1.120 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2026 | 162 | 1.110 |
Why?
|
| Peptide Fragments | 4 | 2025 | 417 | 1.110 |
Why?
|
| Adult | 29 | 2026 | 17398 | 1.080 |
Why?
|
| Female | 42 | 2026 | 34095 | 1.030 |
Why?
|
| Pre-Eclampsia | 3 | 2024 | 72 | 1.030 |
Why?
|
| Myocardial Ischemia | 2 | 2025 | 120 | 1.020 |
Why?
|
| Cardiac Rehabilitation | 2 | 2025 | 76 | 0.990 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2026 | 14 | 0.950 |
Why?
|
| Humans | 54 | 2026 | 65268 | 0.930 |
Why?
|
| Atrial Flutter | 1 | 2026 | 33 | 0.920 |
Why?
|
| Telemedicine | 3 | 2025 | 371 | 0.900 |
Why?
|
| Nutrition Surveys | 5 | 2022 | 149 | 0.890 |
Why?
|
| Narration | 1 | 2025 | 54 | 0.870 |
Why?
|
| Contraception | 2 | 2022 | 72 | 0.850 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 20 | 0.840 |
Why?
|
| Young Adult | 11 | 2025 | 4822 | 0.830 |
Why?
|
| Echocardiography | 5 | 2024 | 509 | 0.820 |
Why?
|
| Prenatal Care | 1 | 2025 | 171 | 0.810 |
Why?
|
| Mobile Applications | 1 | 2025 | 140 | 0.760 |
Why?
|
| Counseling | 1 | 2025 | 376 | 0.750 |
Why?
|
| Obesity | 3 | 2026 | 1274 | 0.740 |
Why?
|
| Contraceptive Effectiveness | 1 | 2022 | 3 | 0.730 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2023 | 169 | 0.730 |
Why?
|
| Patient Compliance | 1 | 2024 | 370 | 0.720 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 12 | 0.720 |
Why?
|
| Tachycardia, Ventricular | 1 | 2024 | 131 | 0.720 |
Why?
|
| Atrial Fibrillation | 3 | 2026 | 884 | 0.710 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 2021 | 22 | 0.690 |
Why?
|
| Health Promotion | 1 | 2025 | 522 | 0.650 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 150 | 0.640 |
Why?
|
| Cardiology | 1 | 2022 | 170 | 0.620 |
Why?
|
| Qualitative Research | 1 | 2024 | 752 | 0.620 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 10 | 0.610 |
Why?
|
| United States | 13 | 2026 | 8122 | 0.580 |
Why?
|
| C-Reactive Protein | 4 | 2025 | 169 | 0.560 |
Why?
|
| Risk Factors | 10 | 2026 | 5447 | 0.560 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 179 | 0.550 |
Why?
|
| Ventricular Remodeling | 3 | 2026 | 95 | 0.530 |
Why?
|
| Point-of-Care Systems | 1 | 2018 | 131 | 0.490 |
Why?
|
| Middle Aged | 19 | 2026 | 18327 | 0.470 |
Why?
|
| Pregnancy Outcome | 3 | 2026 | 197 | 0.440 |
Why?
|
| Cross-Sectional Studies | 7 | 2025 | 2710 | 0.420 |
Why?
|
| Health Surveys | 1 | 2015 | 316 | 0.410 |
Why?
|
| Biomarkers | 7 | 2025 | 1482 | 0.390 |
Why?
|
| Aged | 12 | 2026 | 15010 | 0.360 |
Why?
|
| Stroke Volume | 3 | 2023 | 342 | 0.350 |
Why?
|
| Sinusitis | 1 | 2011 | 21 | 0.340 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 735 | 0.340 |
Why?
|
| Vital Capacity | 1 | 2011 | 122 | 0.340 |
Why?
|
| Forced Expiratory Volume | 1 | 2011 | 212 | 0.330 |
Why?
|
| Endoscopy | 1 | 2011 | 92 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2025 | 767 | 0.320 |
Why?
|
| Cystic Fibrosis | 1 | 2011 | 126 | 0.310 |
Why?
|
| Male | 19 | 2026 | 31123 | 0.310 |
Why?
|
| Gout | 3 | 2015 | 48 | 0.290 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 803 | 0.280 |
Why?
|
| Heart | 3 | 2019 | 298 | 0.280 |
Why?
|
| Furosemide | 2 | 2018 | 19 | 0.250 |
Why?
|
| Retrospective Studies | 8 | 2026 | 6897 | 0.250 |
Why?
|
| Sodium | 2 | 2023 | 60 | 0.250 |
Why?
|
| Diuretics | 2 | 2018 | 58 | 0.250 |
Why?
|
| Atrial Remodeling | 1 | 2026 | 23 | 0.240 |
Why?
|
| Adiposity | 1 | 2026 | 89 | 0.230 |
Why?
|
| Ebstein Anomaly | 1 | 2025 | 5 | 0.230 |
Why?
|
| High-Intensity Interval Training | 1 | 2025 | 2 | 0.220 |
Why?
|
| HMGB1 Protein | 1 | 2025 | 26 | 0.220 |
Why?
|
| Glucose | 2 | 2023 | 477 | 0.220 |
Why?
|
| Peripartum Period | 1 | 2024 | 17 | 0.210 |
Why?
|
| Medication Adherence | 1 | 2025 | 199 | 0.210 |
Why?
|
| Heart Diseases | 2 | 2024 | 223 | 0.210 |
Why?
|
| Smartphone | 1 | 2025 | 73 | 0.210 |
Why?
|
| Troponin T | 2 | 2023 | 24 | 0.200 |
Why?
|
| Ventricular Function, Left | 2 | 2026 | 284 | 0.200 |
Why?
|
| Dyspnea | 1 | 2024 | 120 | 0.200 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2024 | 102 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2025 | 214 | 0.190 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2023 | 45 | 0.190 |
Why?
|
| Heart Ventricles | 2 | 2023 | 267 | 0.190 |
Why?
|
| Focus Groups | 1 | 2024 | 326 | 0.190 |
Why?
|
| Sex Factors | 1 | 2025 | 992 | 0.190 |
Why?
|
| Electrocardiography | 2 | 2024 | 553 | 0.190 |
Why?
|
| Sterilization, Reproductive | 1 | 2022 | 10 | 0.180 |
Why?
|
| Case-Control Studies | 1 | 2025 | 1141 | 0.180 |
Why?
|
| Catheter Ablation | 1 | 2024 | 160 | 0.180 |
Why?
|
| Health Behavior | 1 | 2025 | 484 | 0.180 |
Why?
|
| Insulin Resistance | 1 | 2025 | 415 | 0.170 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2021 | 5 | 0.170 |
Why?
|
| Health Status Disparities | 1 | 2023 | 147 | 0.170 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 326 | 0.170 |
Why?
|
| Vital Signs | 1 | 2021 | 11 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 102 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2022 | 162 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2022 | 202 | 0.160 |
Why?
|
| Diet, Fat-Restricted | 1 | 2020 | 34 | 0.160 |
Why?
|
| Prospective Studies | 2 | 2025 | 3312 | 0.160 |
Why?
|
| Asthma | 1 | 2024 | 483 | 0.150 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2019 | 20 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2024 | 475 | 0.150 |
Why?
|
| Dietary Proteins | 1 | 2019 | 44 | 0.150 |
Why?
|
| Dietary Carbohydrates | 1 | 2019 | 62 | 0.150 |
Why?
|
| Aortic Valve | 1 | 2021 | 181 | 0.150 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 164 | 0.150 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 110 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2025 | 1428 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 704 | 0.140 |
Why?
|
| Aortic Valve Stenosis | 1 | 2021 | 190 | 0.140 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 708 | 0.130 |
Why?
|
| Dopamine | 1 | 2018 | 108 | 0.130 |
Why?
|
| Curriculum | 1 | 2022 | 608 | 0.130 |
Why?
|
| Uric Acid | 2 | 2015 | 47 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2768 | 0.130 |
Why?
|
| Triage | 1 | 2018 | 136 | 0.120 |
Why?
|
| Coronary Circulation | 1 | 2017 | 55 | 0.120 |
Why?
|
| Sarcoidosis | 1 | 2017 | 33 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2026 | 2106 | 0.120 |
Why?
|
| Sleep | 1 | 2019 | 244 | 0.120 |
Why?
|
| Atrial Appendage | 1 | 2017 | 41 | 0.120 |
Why?
|
| Prevalence | 4 | 2026 | 1449 | 0.120 |
Why?
|
| Myocarditis | 1 | 2017 | 71 | 0.120 |
Why?
|
| Gout Suppressants | 1 | 2015 | 22 | 0.110 |
Why?
|
| Infant | 3 | 2023 | 1696 | 0.110 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 292 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2015 | 39 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 230 | 0.110 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 270 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2025 | 146 | 0.100 |
Why?
|
| Hyperuricemia | 1 | 2013 | 7 | 0.100 |
Why?
|
| Receptors, Opioid | 1 | 2012 | 15 | 0.090 |
Why?
|
| Clonidine | 1 | 2012 | 25 | 0.090 |
Why?
|
| Oxycodone | 1 | 2012 | 28 | 0.090 |
Why?
|
| Narcotics | 1 | 2012 | 57 | 0.090 |
Why?
|
| Treatment Outcome | 4 | 2021 | 5801 | 0.090 |
Why?
|
| Analgesics | 1 | 2012 | 102 | 0.090 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2012 | 50 | 0.090 |
Why?
|
| Comorbidity | 2 | 2013 | 1120 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2013 | 178 | 0.080 |
Why?
|
| Disease Progression | 1 | 2015 | 1221 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 154 | 0.080 |
Why?
|
| Diet | 2 | 2023 | 536 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2008 | 46 | 0.070 |
Why?
|
| Cytokines | 1 | 2012 | 951 | 0.070 |
Why?
|
| Stroke | 1 | 2017 | 1212 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2008 | 113 | 0.070 |
Why?
|
| Adolescent | 2 | 2025 | 6318 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1284 | 0.070 |
Why?
|
| Analgesics, Opioid | 1 | 2012 | 528 | 0.060 |
Why?
|
| Glioblastoma | 1 | 2008 | 161 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2008 | 435 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5624 | 0.060 |
Why?
|
| Cushing Syndrome | 1 | 2025 | 9 | 0.060 |
Why?
|
| Renal Artery Obstruction | 1 | 2025 | 17 | 0.060 |
Why?
|
| Aortic Coarctation | 1 | 2025 | 11 | 0.060 |
Why?
|
| Hyperaldosteronism | 1 | 2025 | 8 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2011 | 2062 | 0.060 |
Why?
|
| Thyroid Diseases | 1 | 2025 | 29 | 0.060 |
Why?
|
| Pheochromocytoma | 1 | 2025 | 31 | 0.060 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2025 | 51 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2011 | 2623 | 0.050 |
Why?
|
| Nucleic Acid Heteroduplexes | 1 | 2004 | 14 | 0.050 |
Why?
|
| Peptide Nucleic Acids | 1 | 2004 | 17 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2025 | 61 | 0.050 |
Why?
|
| Physical Conditioning, Animal | 1 | 2025 | 47 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2024 | 22 | 0.050 |
Why?
|
| Home Care Services | 1 | 2025 | 104 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2004 | 115 | 0.050 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.050 |
Why?
|
| Hospitalization | 2 | 2025 | 1398 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1098 | 0.050 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 101 | 0.050 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 93 | 0.050 |
Why?
|
| Heart Atria | 1 | 2023 | 137 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 121 | 0.050 |
Why?
|
| Vegetables | 1 | 2022 | 68 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2026 | 897 | 0.050 |
Why?
|
| Registries | 1 | 2026 | 929 | 0.040 |
Why?
|
| Prognosis | 1 | 2026 | 1785 | 0.040 |
Why?
|
| Child | 1 | 2011 | 4614 | 0.040 |
Why?
|
| Systole | 1 | 2021 | 109 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2020 | 85 | 0.040 |
Why?
|
| Smoking | 1 | 2024 | 862 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 106 | 0.040 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 11 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 160 | 0.030 |
Why?
|
| Creatinine | 1 | 2018 | 136 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 175 | 0.030 |
Why?
|
| Contraindications, Drug | 1 | 2017 | 1 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2025 | 3488 | 0.030 |
Why?
|
| Nitrogen Radioisotopes | 1 | 2017 | 16 | 0.030 |
Why?
|
| Hyperemia | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 463 | 0.030 |
Why?
|
| Ammonia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2017 | 73 | 0.030 |
Why?
|
| Vasodilation | 1 | 2017 | 35 | 0.030 |
Why?
|
| Acute Disease | 1 | 2018 | 662 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 221 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 102 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 62 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2017 | 53 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 168 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 196 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1192 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 2486 | 0.030 |
Why?
|
| Therapeutics | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice | 2 | 2025 | 11131 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 484 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 381 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1113 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 169 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 317 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2017 | 527 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 930 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 857 | 0.020 |
Why?
|
| Animals | 2 | 2025 | 21373 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2012 | 199 | 0.020 |
Why?
|
| Drug Overdose | 1 | 2012 | 122 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2015 | 464 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1656 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3769 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 853 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 12 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 108 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2008 | 286 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2008 | 203 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2008 | 426 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 450 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2008 | 518 | 0.020 |
Why?
|
| Caspases | 1 | 2008 | 176 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 611 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2008 | 962 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2008 | 631 | 0.010 |
Why?
|
| Mitochondria | 1 | 2008 | 410 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1039 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 982 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 1640 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 858 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2008 | 3154 | 0.010 |
Why?
|